Physician profile
Maria Basedow
NPI 1689108060
$1,650.65
in general payments reported to CMS, 2019-2025
16 companies · $609 in 2025
The $609 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $29.85 · 2023: $219 · 2024: $794 · 2025: $609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,621.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,620.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $406.35 | 2023-2025 | |
| Abbvie INC. | $390.35 | 2023-2025 | Qulipta, Ubrelvy |
| Lilly USA, LLC | $260.94 | 2023-2025 | Zepbound, Mounjaro, Trulicity |
| Novo Nordisk INC | $126.46 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $67.14 | 2023-2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.69 | 2020-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $60.95 | 2024-2025 | Shingrix, Arexvy, Bexsero |
| Abbott Laboratories | $58.53 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals LP | $48.41 | 2023-2025 | Airsupra, Breztri |
| Phathom Pharmaceuticals, INC. | $34.43 | 2024 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $31.23 | 2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $30.56 | 2024-2025 | Eliquis |
| Sumitomo Pharma America, INC. | $22.69 | 2025 | Gemtesa |
| Dexcom, INC. | $19.46 | 2025 | Dexcom G6 Transmitter |
| Bausch Health US, LLC | $13.36 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $13.10 | 2024 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Basedow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.